Reversible versus irreversible activation

In this episode of the Talking Biotech podcast, Dr. Kevin Folta speaks with Dr. Neela Patel and Dr. Diane Hollenbaugh from Bonum Therapeutics about the emerging field of conditionally active biologics. They discuss the challenges of current therapies, the innovative mechanisms behind their drug development, and the potential of immuno-oncology to revolutionize cancer treatment. The conversation also covers the market landscape, the origin story of Bonum, and the future directions for their pipeline, emphasizing the importance of targeted therapies in improving patient outcomes.